Use of peptide ll-37 as a therapeutic agent

Utilisation d'un peptide en tant qu'agent thérapeutique


The present invention is directed to the use of the peptide compound Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-lle-Gly-Lys-Glu-Phe-Lys-Arg-lle-Val-Gln-Arg-lle-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-lle-Gly-Lys-Glu-Phe-Lys-Arg-lle-Val-Gln-Arg-lle-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
La présente invention concerne l'utilisation du composé peptidique Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-lle-Gly-Lys-Glu-Phe-Lys-Arg-lle-Val-Gln-Arg-lle-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-NH2 en tant qu'agent thérapeutique destiné à la prophylaxie et/ou au traitement du cancer, de maladies auto-immunes, de maladies fibreuses, de maladies inflammatoires, de maladies neurodégénératives, de maladies infectieuses, de maladies pulmonaires, de maladies cardiaques et vasculaires et de maladies métaboliques. Cette invention concerne aussi des compositions pharmaceutiques, de préférence sous la forme d'un lyophilisat, d'une solution tampon liquide ou d'une préparation de lait maternel artificiel ou d'un substitut du lait maternel contenant le peptide Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-lle-Gly-Lys-Glu-Phe-Lys-Arg-lle-Val-Gln-Arg-lle-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-NH2, éventuellement avec au moins un véhicule, un cryoprotecteur, un lyoprotecteur, un excipient et/ou un diluant pharmaceutiquement acceptable.




Download Full PDF Version (Non-Commercial Use)

Patent Citations (6)

    Publication numberPublication dateAssigneeTitle
    EP-1358888-A1November 05, 2003Robert Bals, Andreas Rembert Koczulla, von Degenfeld, GeorgesL'Antibiotique peptidique humain LL-37/hCAP-18 est un inducteur de l'angiogénèse
    US-2002072495-A1June 13, 2002Oleg Chertov, Oppenheim Joost J., De Yang, Anderson Glenn M., Wooters Joseph M.LL-37 is an immunostimulant
    WO-2004034061-A2April 22, 2004Mabtech AbMethode diagnostique
    WO-2004098536-A2November 18, 2004The Regents Of The University Of California, National Jewish Medical And Research CenterActivite antivirale de peptides cathelicidiniques
    WO-2007076162-A2July 05, 2007Kansas State University Research FoundationPeptides antimicrobiens de cathelicidine
    WO-2009010968-A2January 22, 2009Yitzchak HillmanDisease treatment via antimicrobial peptides or their inhibitors

NO-Patent Citations (4)

    BALS ROBERT ET AL: "The peptide antibiotic LL-37/hCAP-18 is expressed in epthelia of the human lung where it has broad antimicrobial activity at the airway surface", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 95, no. 16, 4 August 1998 (1998-08-04), pages 9541 - 9546, XP002157167, ISSN: 0027-8424
    KOJI FUKUMOTO ET AL: "Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats", PEDIATRIC SURGERY INTERNATIONAL, SPRINGER, BERLIN, DE, vol. 21, no. 1, 1 January 2005 (2005-01-01), pages 20 - 24, XP019339809, ISSN: 1437-9813
    SANDRA TJABRINGA G ET AL: "The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung", PULMONARY PHARMACOLOGY AND THERAPEUTICS, ACADEMIC PRESS, NEW YORK, NY, US, vol. 18, no. 5, 1 October 2005 (2005-10-01), pages 321 - 327, XP004918514, ISSN: 1094-5539
    SCOTT M G ET AL: "The human antimicrobial peptide LL - 37 is a multifunctional modulator of innate immune responses", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 169, 1 January 2002 (2002-01-01), pages 3883 - 3891, XP002250232, ISSN: 0022-1767

Cited By (0)

    Publication numberPublication dateAssigneeTitle